We are a mental health care company pioneering the development of a new model of psilocybin therapy, in which psilocybin is administered in conjunction with psychological support, to help people with treatment-resistant depression. We have developed a proprietary high-purity polymorphic crystalline formulation of psilocybin, COMP360. In 2019, we completed a Phase I clinical trial administering COMP360, along with psychological support, to 89 healthy volunteers, the largest randomized, controlled trial with psilocybin therapy to date. In this trial, we observed that COMP360 was generally well-tolerated and supported continued progression of Phase IIb studies.